Associations between vitamin D status and biomarkers linked with inflammation in patients with asthma: a systematic review and meta-analysis of interventional and observational studies.
El Abd. Asmae A; Dasari. Harika H; Dodin. Philippe P; Trottier. Helen H; Ducharme. Francine M FM
Key Findings
- Higher serum vitamin D (25(OH)D) is consistently linked to lower IgE levels in asthma patients.
- Some low‑risk studies suggest vitamin D may also reduce blood eosinophils and the peptide LL‑37, though data are limited.
- For most other inflammatory biomarkers, no significant relationship with vitamin D was found.
Practical Outcomes
- Keeping vitamin D in the optimal range (e.g., 30‑50 ng/mL) might modestly reduce allergic inflammation in asthma, which could benefit overall immune balance. Biohackers can test their 25(OH)D levels and consider supplementation if low, but should view the effect as supportive rather than a cure‑all.
Summary
The review looked at many studies on vitamin D levels and inflammation in people with asthma. Overall, most markers didn’t change with vitamin D, but higher vitamin D was linked to lower allergy‑related IgE and possibly fewer eosinophils and less of the antimicrobial peptide LL‑37, hinting that vitamin D can tone down some immune activity.
Abstract
Numerous studies indicate an association between vitamin D status and inflammatory biomarkers in patients with asthma, but findings are inconsistent. This review aims to summarize the relationship between serum vitamin D status, assessed by 25-hydroxyvitamin D (25(OH)D) level, and inflammatory biomarkers in children and adults with asthma. A literature search of interventional and observational studies on 25(OH)D up to November 2022 was conducted across six electronic databases. Outcomes of interest included a range of inflammatory biomarkers classified in four categories: T helper 2 (Th2) pro-inflammatory, non-Th2 pro-inflammatory, anti-inflammatory, and non-specific biomarkers. Study characteristics were extracted and risk of bias was evaluated using the American Academy of Nutrition and Dietetics tool. Meta-analysis was conducted on studies with a low risk of bias, while narrative reporting was used to present the direction of associations (positive, no association, or negative) for each biomarker, overall and within the low-risk studies. We included 71 studies (3 interventional, 68 observational) involving asthma patients. These studies investigated the association between serum 25(OH)D and Th2 pro-inflammatory biomarkers (N = 58), non-Th2 pro-inflammatory biomarkers (N = 18), anti-inflammatory biomarkers (N = 16), and non-specific biomarkers (N = 10). Thirteen (18.3%) studies, 50 (70.4%), and 8 (11.3%) were at high, moderate, and low risk of bias, respectively. In all studies, irrespective of risk of bias, the most frequently reported finding was no significant association, followed by a negative association between 25(OH)D and pro-inflammatory biomarkers and a positive association with anti-inflammatory biomarkers. In low-risk studies, one biomarker could be meta-analysed. The pooled estimate for 25(OH)D and serum IgE showed a negative association (β (95% CI)= - 0.33 (-0.65 to - 0.01); I<sup>2</sup> = 88%; N = 4 studies). A negative association between 25(OH)D and blood eosinophils was also observed in the largest of three studies, as well as with cathelicidin (LL-37) in the only study reporting it. For other biomarkers, most low-risk studies revealed no significant association with 25(OH)D. Serum 25(OH)D is negatively associated with serum IgE and possibly with blood eosinophils and LL-37, supporting an in vivo immunomodulatory effect of 25(OH)D. Future research should employ rigorous methodologies and standardized reporting for meta-analysis aggregation to further elucidate these associations.
Study Information
pubmed
2024
2024-09-19T00:00:00.000Z
10.1186/s12931-024-02967-z
3
122